Meeder Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Meeder Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-475	Closed	-$11K	–	1945
2018 Q4	$11K	Buy	+475	New	+$12.3K	﹤0.01%	1233
2018 Q3	–	Sell	-71	Closed	-$1.91K	–	1760
2018 Q2	$1.91K	Sell	71 -441	-86%	-$13.5K	﹤0.01%	1424
2018 Q1	$16K	Buy	512 +7	+1%	+$246	﹤0.01%	950
2017 Q4	$19K	Buy	+505	New	+$16.3K	﹤0.01%	944
2017 Q2	–	Sell	-132	Closed	-$3K	–	1992
2017 Q1	$3K	Buy	+132	New	+$2.71K	﹤0.01%	1308

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Meeder Asset Management's AIMT Position: Q1 2019 in Review

Meeder Asset Management sold out of Aimmune Therapeutics (AIMT) in Q1 2019, closing a stake of 475 shares — an estimated $11K sold.

Meeder Asset Management first reported a position in AIMT in Q1 2017 and held it in 5 quarters. The position peaked at $19K in Q4 2017. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

Meeder Asset Management reported no remaining Aimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
Meeder Asset Management sold 475 Aimmune Therapeutics shares in Q1 2019, an estimated $11K.
Meeder Asset Management first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 5 quarters.
Meeder Asset Management's Aimmune Therapeutics position peaked at $19K in Q4 2017.
125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.